

Press Release



ASKA Pharmaceutical Terminates Joint Development and Option Agreement for a PMS/PMDD Agent with Renascience

TOKYO, November 25, 2024 - ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886) announced that ASKA has decided to terminate the joint development and option agreement for a PMS/PMDD agent under development by Renascience Inc. (Head Office: Chuo-Ku, Tokyo, President: Keisuke Furuta, hereinafter “Renascience”).

This agreement was entered into on December 24, 2019, as an option agreement to obtain a right of first negotiation to obtain an exclusive license to develop and commercialize the PMS/PMDD agent being developed by Renascience in Japan.

Renascience conducted an investigator-initiated Phase II clinical trial in collaboration with medical institutions, but ASKA decided not to exercise the option.

There will be no impact on the Company’s consolidated financial results for FY2024.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp